Epizyme to Participate in Upcoming Healthcare Conferences in March 2022
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets, today announced its participation in two investor conferences in March.
Cowen 42nd Annual Health Care Conference
Shefali Agarwal, Chief Medical Officer, will participate in the Cowen 42nd Annual Health Care Conference as part of the Targeted Oncology panel.
Tuesday, March 8, at 9:10am EST
Barclays Global Healthcare Conference
Grant Bogle, Chief Executive Officer, will participate in a fireside chat at the Barclays Global Healthcare Conference.
Tuesday, March 15, 2022, at 2:05pm EST
Live webcasts of the presentations will be available under the investor section of the Company’s website at www.epizyme.com, and will be archived for 60 days following the event.
About Epizyme, Inc.
Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer through novel epigenetic medicines. The Company is focused on creating medicines that are targeted at specific causes of diseases, that are orally administered, tolerable, easy to take and based on a deep understanding of the patients that may benefit from them. The Company aspires to change the standard-of-care for patients and physicians by developing medicines with fundamentally new mechanisms of action. For more information, visit www.epizyme.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220228005306/en/
Source: Epizyme, Inc.
View this news release online at: